Vogler S. Can we achieve affordable cancer medicine prices? Developing a pathway for change. Expert Review of Pharmacoeconomics & Outcomes Research. 2021: 1-5

Vogler S, Zimmermann N, Babar-Ud-Din Z, Busse R, Espin Balbino J, et al.: Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. Journal of Pharmaceutical Policy and Practice 2021; 14(18)


Vogler S, Schneider P, Lepuschütz L.: Impact of changes in the methodology of external price referencing on medicine prices:discrete-event simulation. Cost Effectiveness and Resource Allocation 2020; 18(51)

Gombocz M, Vogler S.: Public spending on orphan medicines: a review of the literature. Journal of Pharmaceutical Policy and Practice 2020; 13 (66)

Vogler S, Fischer S.: How to address medicines shortages: Findings from a cross-sectional study of 24 countries. Health Policy 2020; 124(12): 1287-1296

Gamba S, Pertile P, Vogler S.: The impact of managed entry agreements on pharmaceutical prices. Health Economics 2020; 29 (S1): 47-62

Rintoul A, Colbert A, Garner S, Kotwani A, Vogler S, Bouvy J et al.: Medicines with one seller and many buyers: strategies to increase the power of the payer. BMJ 2020; 369: m1705 

Ferrario A, Dedet G, Humbert T, Vogler S, Suleman F, Pedersen H.: Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ 2020; 368 :l5444


Vogler S, Zimmermann N, Haasis MA, Babar-Ud-Din Z, Busse R, Espin Balbino J, et al.: Can pharmaceutical pricing and reimbursement policies make a difference in promoting equitable access to affordable medicines? From diagnosis to sustainable impact. Editorial. 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies: Vienna, Austria. 23-24 October 2019. Journal of Pharmaceutical Policy and Practice. 2019;12(Suppl 1):34

Vogler S.: Il miglioramento dei processi, la cooperazione, l’evidenza e la trasparenza: i temi chiave per le proposte di riforma delle politiche sul prezzo e rimborso dei farmaci. (Title in English: Improvement of processes, cooperation, evidence and transparency: the key proposals for reforming pharmaceutical pricing and reimbursement policies) Politiche sanitarie 2019; 20(4):180-182

Vogler S, Dedet G, Bak Pedersen H.: Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries. Appl Health Econ Health Policy 17 2019; 803–816; doi:10.1007/s40258-019-00509-z

Vogler S, Schneider P, Dedet G, Bak Pedersen H. Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan. International Journal for Equity in Health. 2019;18(1):89

Vogler S.: Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies. Empirica - Journal of European Economics 2019; 46(3), 443-469

Vogler S, Schneider P.: Assessing Data Sources for Medicine Price Studies. International Journal of Technology Assessment in Health Care 2019; 35(2): 106-115

Vogler S, Schneider P, Zimmermann N.: Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing. PharmacoEconomics - Open (2019) 3:303–309 

Mardetko N, Kos M, Vogler S.: Review of studies reporting actual prices for medicines. Expert review of pharmacoeconomics & outcomes research 2019; 19(2): 159-179


Vogler S, de Rooij R.: Medication wasted – Contents and costs of medicines ending up in household garbage. Research in Social and Administrative Pharmacy, 2018, Volume 14, Issue 12, December 2018, Pages 1140-1146


Gammie T, Vogler S, Babar Z-U-D.: Economic Evaluation of Hospital and Community Pharmacy Services: A Review of the Literature (2010-2015). Annals of Pharmacotherapy, 51(1): 54-65, 2017

Schneider P, Renner A, Bobek J, Vogler S, Ostermann H.: Economic Evaluation of Minor Ailment Schemes (MAS). DOI: 10.1055/s-0042-120488, Gesundheitsökonomie & Qualitätsmanagement, 2017, 22(S 01): S23-S29

Morgan S, Vogler S, Wagner A.: Payers’ experiences with confidential pharmaceutical Price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy, 121, Issue 4: 354-362, April 2017,

Pauwels K, Huys I, Vogler S, Casteels M, Simoens S.: Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Frontiers in Pharmacology, 2017, doi: 10.3389/fphar.2017.00171

Schneider P, Vogler S, Zimmermann N.: Oberes Mittelfeld - Ergebnisse einer Preisvergleichsstudie zu kostenintensiven Arzneimitteln. (Title in English: Upper midrange - anaylsis of high priced medicines in Austria), Das österreichische Gesundheitswesen – ÖKZ, 58. Jg. (2017), 05: 15-17, 2017

Vogler S, Paterson K.: Can Price Transparency Contribute to More Affordable Patient Access to Medicines?. PharmacoEconomics Open, 1 (3): 145-147, 2017

Vogler S, Gombocz M, Zimmermann N.: Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the Netherlands. Journal of Pharmaceutical Health Services Research, 2017, Volume 8, Issue 3, September 2017, Pages 147-158

Vogler S, Schneider P.: Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey. Generics and Biosimilars Initiative Journal (GaBI Journal), 6(2): 79-88, 2017

Vogler S, Paris V, Ferrario A, Wirtz V, de Joncheere K, Schneider P.: How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Applied Health Economics and Health Policy, 15: 307-321, 2017


Vogler S, Babar Z-U-D, Vitry A.: Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. The Lancet Oncology 17(1), No. 1: 39-47, 2016

Vogler S, Zimmermann N, Ferrario A, Wirtz V, de Joncheere K, Bak Pedersen H, Dedet G, Paris V, Mantel-Teeuwisse A, Babar Z-U-D and on behalf of the Scientific Programme Committee: Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. Journal of Pharmaceutical Policy and Practice, 9: 9, 2016

Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, De Joncheere K, Hill S. : Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med, 13: 5, 2016

Pani L, Montilla S, Németh G, Russo P, Viceconte G, Vogler S.: Balancing Access to Medicines and Sustainability in Europe: an Analysis from the Network of Competent Authorities on Pricing and Reimbursement (CAPR). Pharmacological Research, S1043-6618(16)30202-X, 2016

Vogler S, Habimana K, Zimmermann N.: Stakeholder preferences about policy objectives and measures of pharmaceutical pricing and reimbursement . Health Policy and Technology, 5; Issue 3: 213–225 , September 2016

Vogler S, Zimmermann N, de Joncheere K.: Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015. Health Policy, 120, Issue 12: 1363–1377, December 2016

Vogler S, Zimmermann N, Babar Z-U-D: Price comparison of high-cost originator medicines in European countries. Expert Review of Pharmacoeconomics & Outcomes 17 (2): 221-230


Vogler S, Kilpatrick K, Babar Z-U-D.: Analysis of Medicine Prices in New Zealand and 16 European Countries. Value in Health 2015, 18(4), 2015

Vogler S, Österle A, Mayer S.: Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries. International Journal for Equity in Health, 14: 124, 2015


Vogler S, Zimmermann N.: Aktivitäten von Krankenversicherungsträgern zur Etablierung eines rationalen Einsatzes von Arzneimitteln. Im Blickpunkt, 1/2014, 2014

Vogler S, Leopold C, Zimmermann N, Habl C, de Joncheere K.: The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative-Experiences from engaging with pharmaceutical policy makers. Health Policy and Technology 2014, 3: 139-148, 2014

Vogler S, Leopold C, Zuidberg C, Habl C.: Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna. Journal of Pharmaceutical Policy and Practice 2014, 7(1): 6, 2014

Vogler S, Habimana K, Arts D.: Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries. Health Policy 2014, 117(3): 311-327, 2014

Leopold C, Mantel-Teeuwisse A.K, Vogler S, Valkova S, de Joncheere K, Leufkens H.G.M, Wagner A, Ross-Degnan D, Laing R.: Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bulletin of the World Health Organization 2014 , 92:630-640D

Leopold C, Zhang F, Mantel-Teeuwisse A.K., Vogler S, Valkova S, Ross-Degnan D, Wagner A.K.: Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. International Journal for Equity in Health 2014 , 13:53

Babar Z-U-D, Gray A, Kiani A, Vogler S, Ballantyne P, Scahill S. : The future of medicines use and access research: using the Journal of Pharmaceutical Policy and Practice as a platform for change. Journal of Pharmaceutical Policy and Practice 2014, 7(1): 1-2, 2014

Vogler S, Zimmermann N, Mazag J.: Availability and procurement conditions of originator and generic medicines in hospitals – an exploratory study in five medium-sized European countries. Generics and Biosimilars Initiative Journal (GaBI Journal) 2014, 3(4): 168-75, 2014


Vogler S, Zimmermann N, Leopold C, Habl C, Mazag J.: Discounts and Rebates Granted for Medicines for Hospital Use in Five European Countries. The Open Pharmacoeconomics & Health Economics Journal 2013, 5: 1-10, 2013

Vogler S, Zimmermann N, Habl C, Mazag J. : The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. Cost Effectiveness and Resource Allocation 2013, 11: 15, 2013

Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, Malmström R, Vogler S, Godman B, Gustafsson LL.: Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. European Journal of Clinical Pharmacology 2013, 69(1): 73-8, 2013

Leopold C, Mantel-Teeuwisse A.K, Vogler S, de Joncheere K, Laing R.O, Leufkens H.G.M.: Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy 2013, 112: 209-16, 2013

Vogler S, Zimmermann N.: How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria. Generics and Biosimilars Initiative Journal (GaBI Journal) 2013, 2(2): 65-75, 2013

Leopold C, Vogler S, Piessnegger J, Bucsics A.: Aktuelle Heilmittelausgaben und arzneimittelpolitische Trends in Europa. Soziale Sicherheit 2013, 9: 414-429, 2013

Leopold C, Vogler S, Habl C, Mantel-Teeuwisse A.K, Espin J.: Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab. Health Policy 2013, 113(3): 313–22, 2013

Vogler S, Zimmermann N, Habl C.: Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries. Generics and Biosimilars Initiative Journal (GaBI Journal) 2013, 2(4): 178-87, 2013


Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A.: Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review 2012, 5(1): 38-46, 2012

Vogler S.: The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview. Generics and Biosimilars Initiative Journal (GaBI Journal) 2012, 1(2): 93-100, 2012

Vogler S.: Preisbildung und Erstattung von Arzneimitteln in der EU - Gemeinsamkeiten, Unterschiede und Trends. [Title translated in English: Pricing and reimbursement of medicines in the EU], Pharmazeutische Medizin 2012, 14: 48-56, 2012

Leopold C, Vogler S, Mantel-Teeuwisse A, de Joncheere K, Leufkens H.G.M, Laing R.: Differences in external price referencing in Europe - A descriptive overview. Health Policy 2012, 104: 1, 2012

Vogler S.: How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. Farmeconomia: Health economics and therapeutic pathways 2012, 13 (Suppl 3): 29-41, 2012

Vogler S, Zimmermann N.: The potential of generics policies: more room for exploitation. PPRI Conference Report. Generics and Biosimilars Initiative Journal (GaBI Journal) 2012, 1(3-4): 146-9, 2012

Leopold C, Mantel-Teeuwisse A.K, Seyfang L, Vogler S, de Joncheere K, Laing R.O, Leufkens H.G.M.: Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries. Southern Med Review 2012, 5(2): 34-41, 2012


Vogler S, Habl C, Bogut M, Voncina L.: Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croatian Medical Journal (CMJ) 2011, 52: 183-97, 2011

Vogler S, Zimmermann N, Mazag J.: Procuring medicines in hospitals: results of the European PHIS survey. European Journal of Hospital Pharmacy Practice 2011, 17: 20-21, 2011

Editors of Medical Tribune.: Weltweit ähnliche Probleme: Arzneien & Sparzwang. [Title translated in English: Worldwide similar problems: Medicines & the need for cost-savings], 2011

Vogler S, Zimmermann N, Leopold C, de Joncheere K.: Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review 2011, 4: 22-32, 2011


Vogler S.: A European survey on medicines management in hospitals. European Journal of Hospital Pharmacy Practice 2010, 16: 12, 2010


Vogler S, Espin J, Habl C.: Pharmaceutical Pricing and Reimbursement Information (PPRI) – new PPRI analysis including Spain. Pharmaceuticals Policy and Law 2009, 11: 213-34, 2009


Vogler S.: Arzneimittelpreisbildung und Arzneimittelerstattung in der EU. [Title translated in English: Pharmaceutical pricing and reimbursement in the EU], Austrian Public Health Association Newsletter 2008, 4: 1-2, 2008

Leopold C, Vogler S, Habl C.: Was macht ein erfolgreiches Referenzpreissystem aus – Erfahrungen aus internationaler Sicht. [Title translated in English: Implementing a successful reference price system – Experiences from other countries], Soziale Sicherheit 2008, 11: 614-23, 2008


Vogler S, Habl C, Leopold C.: Arzneimittel – wer zahlt? Erstattung und Selbstbeteiligung in der erweiterten EU. [Title translated in English: Pharmaceuticals: Who pays? Reimbursement and co-payments in the enlarged EU], Soziale Sicherheit 2006, 9: 411-8, 2006

Arts D, Habl C, Rosian I, Vogler S.: Pharmaceutical Pricing and Reimbursement Information (PPRI): a European Union project. Italian Journal of Public Health 2006, 3: 36-40, 2006


Rosian I, Vogler S, Vander Stichele R, Larsen L, Odegaard B, Brahm A, et al.: EURO-MED-STAT–Monitoring expenditure and utilization of medicinal products in the European Union countries: a Public Health approach. European Journal of Public Health, 13 (3 Supplement): 95-100, 2003


Rosian I, Vogler S.: Arzneimittelsysteme in Europa – ein vergleichender Überblick. [Title translated in English: Pharmaceutical systems in Europe – a comparative overview], Soziale Sicherheit 2002, 4: 165-74, 2002